Pilot study of interferon-α-ribavirin-interleukin-2 for treatment of nonresponder patients with severe liver disease infected by hepatitis C virus genotype 1

Journal of Viral Hepatitis

Volumn 13, Issue 2, 2006, Pages 139-144

  Alric, L ^a,b   Thebault, S ^a   Peron, J M ^a   Balard, P ^b   Metivier, S ^a   Pipy, B ^b   Izopet, J ^a   Vinel, J P ^a  

^a CHU PURPAN   (France)

^b CHU RANGUEIL   (France)

Author keywords

Hepatitis; Hepatitis C virus; Immunotherapy; Interleukin 2; Nonresponders

Indexed keywords

ALPHA2A INTERFERON; COLONY STIMULATING FACTOR 1; INTERLEUKIN 2; PEGINTERFERON; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 1; HUMAN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LIVER DISEASE; LIVER FIBROSIS; MALE; MYALGIA; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS NODULE; THROMBOCYTOPENIA; VIRUS LOAD; VIRUS STRAIN;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; INTERLEUKIN-2; MALE; MIDDLE AGED; PILOT PROJECTS; RIBAVIRIN; SPECIES SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33645106780     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00694.x     Document Type: Article

References (24)

1. Tong MJ El-Farra NS Reikes AR Co RL Clinical outcomes after transfusion-associated hepatitis C N Engl J Med 1995 332 1463 1466
2. McHutchinson J Gordon S Schiff E et al. Interferon alfa- 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C N Engl J Med 1998 339 1485 1492
3. Manns MP McHutchinson JG Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 2001 358 958 965
4. Fried MW Shiffman ML Reddy KR et al. Peginterferonalfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 2002 347 975 982
5. Lechner F Wong DKH Dunbar R et al. Analysis of successful immune responses in persons infected with hepatitis C virus J Exp Med 2000 191 1499 1592
6. Eckels DD Wang H Bian TH Tabatabai N Gill JC Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T Cells in HCV infection Immunol Rev 2000 174 90 97
7. Alric L Fort ML Izopet J et al. Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection Gastroenterology 1999 113 1675 1681
8. Koziel MJ Cytokines in viral hepatitis Sem Liv Dis 1999 19 169
9. Kamal SM Fehr J Roesler B Peters T Rasenack JW Peginterferon alone or with ribavirin enhances HCV- specific CD4+ T-helper 1 responses in patients with chronic hepatitis C Gastroenterology 2002 123 1070 1083
10. Levy Y Houhou S Carriere I et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial Lancet 1999 353 923 929
11. The French METAVIR Cooperative Group Bedossa P Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C Hepatology 1994 20 15 21
12. Alric L Duffaut M Selves J et al. Maintenance therapy with gradual reduction of interferon dose over one year improves histological response in patient with chronic hepatitis C with biochemical response: results of a randomized trial J Hepatol 2001 35 272 278
13. Shiffman ML Hofmann CM Contos MJ et al. Randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia Gastroenterology 1999 117 1164 1172
14. Chang KM Thimme R Melpolder JJ et al. Differential CD4+ and CD8+ T-cell responsiveness in hepatitis C virus infection Hepatology 2001 33 267 276
15. Rahman F Heller T Sobao Y et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C Hepatology 2004 40 87 97
16. Li XC Demirci G Berrari-Lacraz S et al. IL-15 and IL-2: a matter of life and death for T cells in vivo Nat Med 2001 7 114 118
17. Kovacs JA Baseler M Dewar RJ et al. Increases in CD4 T lymphocytes with intermitent courses of interleukin-2 in patients with human immunodeficiency virus infection N Engl J Med 1995 332 567 575
18. Valdez H Metcalf JA Gripshover BM Jacobson JM Mitsuyasu R Lederman MM Effect of IL-2 therapy on plasma hepatitis C virus- RNA levels in HIV/hepatitis C virus co-infected patients AIDS 2001 15 661 662
19. Thibault V Delaugerre C Calvez V Costagliola D Tubiana R Katlama C Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results for a randomized control trial Hepatology 2002 35 238 239
20. Schlaak JF Radecke K Buschenfelde KH Gerken G Sustained suppression of HCV replication and inflammatory activity after interleukin-2 therapy in patients with HIV/hepatitis C virus coinfection J acquir Immune Defic Syndr 2002 29 145 148
21. Pardo M Castillo I Olivia H et al. A pilot study of recombinant interleukin-2 treatment of chronic hepatitis C Hepatology 1997 26 1318 1321
22. Kozlowski A Charles SA Harris JM Development of pegylated interferons for the treatment of chronic hepatitis C Bio Drugs 2001 15 419 429
23. Pockros PJ Patel K O'Brien C et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients non responsive to previous therapy Hepatology 2003 37 1368 1374
24. Bergqvist A Rice C Transcriptional activationof the interleukin-2 promoter by hepatitis C virus core protein J Virol 2001 75 772 781